Next Phase Newsletter

A healthcare and life sciences focused venture capital firm with USA and China offices has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally.

The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data.

The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in the UK and USA is actively seeking innovative investment opportunities with high potential for growth. With its current fund, the firm invests in digital technologies in the life sciences space. The firm prefers to invest in venture to growth stage companies – in general, companies looking for seed funding will be considered too early-stage for the firm. With this fund, the firm seeks to make 18-20 investments with initial investment sizes in the range of $3-10M. The firm will focus on companies that are based in the UK, USA, and Canada, but may review those from other geographies on a case by case basis.

The firm is most interested in life science companies with a digital component. This includes healthcare IT/digital health, utilization of AI/machine learning for drug discovery, genomics, precision medicine, etc. The firm is open to medical devices or diagnostics that have a digital component. In particular, the firm is most interested in technologies that are dedicated to the treatment of chronic disorders and lead to improved outcomes and lower care costs in hospital systems. The firm will not consider traditional biopharmaceutical modalities.

The firm carefully evaluates investment opportunities based on the quality and experienced of the management team as well as market opportunity. The firm is open to both leading and co-investing, and in the former case will seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the US is currently allocating capital from its third fund, investing between $1-2M in pre-seed and seed-stage companies, targeting approximately 10% as their ownership target. The fund is ~75% deployed and expects to make several more investments over the upcoming quarters. The firm will consider opportunities in the United States and Canada.

Within healthcare and life science, the firm is interested in AI-based, non-consumer healthcare IT products. While the firm is open to all indications, the firm is interested in specialist care (i.e., chronic conditions, telehealth), value-based care enablement, behavioral health, elder care, and clinical trial enablement. The consideration of hardware is limited in the healthcare and life science space.

The firm does not have any requirements of the management team. The firm prefers to lead, but will also co-lead and co-invest. They do not require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with strong China expertise and global capabilities discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in US and China.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally change the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not of interest. The firm will invest in Seed stage companies that are currently selling in the market. The firm is open to global companies, typically allocating between $250k-1.5M USD. The firm can act as a lead investor and co-investor.

In terms of life science, the firm invests in cancer-focused digital health companies, however, does not invest in drugs, therapeutics, medical devices, and technologies that require FDA approval.

The firm does not have specific management team requirements and does not require to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A leading European venture capital firm that provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing therapeutic treatments to patients, with a focus on indications with high unmet needs. The firm has a diverse international team in Spain that is driven by science, with the ambition to transform capital into medical breakthroughs. The firm has over €400M million in assets under management through its three funds. The investments typically range from 5 million to 20 million, including additional capital for follow-on investments.

The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new family office fund of a successful hedge fund manager focused on private investments has multiple offices in the US. Due to the single LP structure of the fund, it can be very flexible in terms of investment size and stage. The firm is open to working with companies in the seed, series A, and series B stage with the majority of investments falling in the $500k-2.5M range. The firm also has the ability to allocate $5M or more in situations where they find the opportunity particularly compelling. The firm is capable of both acting as a lead and co-investor, and is primarily focused on companies throughout North America but has exposure to Europe and Asia as well.

The firm has a focus on vertically integrated platforms and software/”software x hardware” systems. Specifically, the firm is interested in AI-enabled drug discovery platforms, lab automation, diagnostics and data collection, and clinical trials management software. The firm is generally agnostic in terms of both stage of development and indication area but is most interested in early stage, highly innovative biotech companies.

The firm is looking for privately held companies with experienced management teams and a product/service with a large addressable market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.